Simple Summary Tyrosine kinase inhibitors (TKIs) are the main class of drugs used to treat
chronic myeloid leukemia. Because most CML patients must remain on TKIs indefinitely, it is …

In the past decade, numerous tyrosine kinase inhibitors (TKIs) have been introduced in the
treatment of chronic myeloid leukemia. Given the significant interpatient variability in TKIs …

Solute carrier (SLC) and ATP-binding cassette (ABC) transporters comprise a variety of
proteins expressed on cell membranes responsible for intrusion or extrusion of substrates …

Leukemia represents a diverse group of hematopoietic neoplasms that can be classified into
different subtypes based on the molecular aberration in the affected cell population …

The hematopoietic neoplasm chronic myeloid leukemia (CML) is a rare disease caused by
chromosomal reciprocal translocation t (9; 22)(q34: q11) with subsequent formation of the …

The effects of polymorphisms of ABCB1 and ABCG2 on the dose‐adjusted plasma trough
concentrations and cerebrospinal fluid (CSF)‐to‐plasma ratios of ponatinib were evaluated …

Chronic myeloid leukemia (CML) is characterized by the possession of the Philadelphia
chromosome, which contains the Bcr-Abl oncogene that codes for the oncoprotein BCR …

Simple Summary Tyrosine kinase inhibitor (TKI) therapy is often taken indefinitely by chronic
myeloid leukemia (CML) patients. However, little is known about the long-term or under …

Background Diminished bioavailability of imatinib in leukemic cells contributes to poor
clinical response. We examined the impact of genetic polymorphisms of imatinib on the …

Ponatinib is an efficient oral tyrosine kinase inhibitor (TKI) for T315I-positive Ph+ ALL and
T315I-positive chronic myeloid leukemia (CML) or BCR-ABL when no other TKIs can be …